Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
Acerta Pharma BV
This study is designed to evaluate PFS endpoint for ACE-196 vs ibrutinib in previously treated chronic lymphocytic leukemia.
Potential participants must have â‰¥ 1 of the following high-risk prognostic factors:
â—¦Presence of 17p del by central laboratory.
â—¦Presence of 11q del by central laboratory